Moran Wealth Management 13F: New $2.9M Stake in GMED

Moran Wealth Management established a brand-new position in Globus Medical, Inc. GMED, according to a Form 13F filing disclosed on October 22, 2026. The firm acquired 38,439 shares of the medical device maker. The stake had an estimated value of $2,879,081 at the time of the report.

GMED Globus Medical, Inc.

$81.66 ▼ -6.46% year to date

1M 3M YTD

Daily close · Oct 22, 2026

What Changed in Moran Wealth Management's Globus Medical Position

Moran Wealth Management did not hold any shares of Globus Medical prior to this filing, making the acquisition a brand-new investment in the healthcare company. The reported purchase of 38,439 shares brought the total value of the holding to nearly $2.88 million. Globus Medical shares closed at $81.66 on the day of the filing.

Other Institutional Activity in Globus Medical

Other large investors adjusted their holdings in the medical device maker during recent periods. Jupiter Topco LLC grew its holdings by 4,100,212 shares, ending with 8,200,423 shares worth about $669,646,572. Kayne Anderson Rudnick Investment Management LLC grew its holdings by 2,139,865 shares, ending with 4,279,730 shares worth about $349,482,767. Bank of Montreal /CAN/ grew its holdings by 118,356 shares, ending with 2,425,491 shares worth about $198,065,603. On the other hand, Sculptor Capital LP reduced its holdings by 58,104 shares to end with 3,000,000 shares valued at $244,980,010. Gw&K Investment Management reduced its holdings by 21,622 shares, ending with 1,494,723 shares worth about $118,098,067.

Globus Medical, Inc. Stock Up 3.0%

Globus Medical shares recently traded around $81.02 as of October 23, 2026, sitting below the event close of $81.66. The stock moves within a 52-week range between $59.51 and $101.40. The medical device company has a market capitalization of approximately $11.0 billion and a price-to-earnings ratio of 20.94.

Recent Earnings

Globus Medical reported trailing twelve-month revenue of $3,144,933,888 with an earnings per share of $3.90. The company achieved a net profit margin of 17.0% and a return on equity of 11.8%. The next quarterly earnings report is scheduled for release on November 5, 2026.

Insider Buying and Selling at Globus Medical, Inc.

Company insiders executed several stock sales over the prior months. General Counsel Kelly Grace Huller sold 20,000 shares on February 25, 2026, at an average price of $94.50 for a total value of $1,890,000. Director David D Davidar sold 25,000 shares on June 5, 2026, at $80.76 per share, totaling $2,019,072. Director Stephen T Zarrilli sold 25,000 shares on August 18, 2026, at $87.04 for $2,175,965. Director James R Tobin sold 30,000 shares on September 15, 2026, at $74.58 for $2,237,502.

Analysts Set New Price Targets

Wall Street firms updated their outlooks on Globus Medical ahead of the filing. On July 13, 2026, RBC Capital maintained an Outperform rating while lowering its price target to $115.00 from $120.00. Truist Securities maintained a Buy rating on July 16, 2026, lowering its target to $100.00 from $115.00. UBS initiated coverage on July 28, 2026, with a Neutral rating and an $82.00 price target. Wells Fargo maintained an Overweight rating on August 7, 2026, adjusting its target from $103.00 down to $99.00. Later, on October 1, 2026, RBC Capital maintained an Outperform rating while lowering its target to $85.00 from $115.00. The stock carries a consensus buy recommendation across thirteen analyst opinions with a mean price target of $100.92.

About Globus Medical, Inc.

Globus Medical, Inc. develops and commercializes medical technology solutions and implants designed to assist patients with musculoskeletal disorders. Headquartered in Audubon, Pennsylvania, the firm serves hospitals and surgical centers globally.

Bottom Line

Investors will look toward the upcoming earnings release on November 5, 2026, for further insight into the financial health of Globus Medical. Future filings will reveal whether institutional buyers continue adding to their positions.